Brief: Biotec Pharmacon Says Woulgan Results Expected In Late Q2

Arcticzymes Technologies ASA

29/01/2019 07:07

Jan 29 (Reuters) - Biotec Pharmacon ASA  BIOTEC.OL :
    * BIOTEC PHARMACON FINALISES POST MARKET STUDY ON WOULGAN
    * RESULTS ARE EXPECTED IN LATE Q2 2019
    * APPLICATION WAS ACCEPTED IN NOVEMBER 2018 AND ALL PATIENTS
HAVE
NOW BEEN TREATED.

Source text for Eikon:  ID:nObiyrklCa 
Further company coverage:  BIOTEC.OL 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))